Presentation is loading. Please wait.

Presentation is loading. Please wait.

Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices  Talia Spanier, MDa, Mehmet Oz, MDa, Howard Levin,

Published byJane Wilcox Modified over 6 years ago

Similar presentations

Presentation on theme: "Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices  Talia Spanier, MDa, Mehmet Oz, MDa, Howard Levin,"— Presentation transcript:

1 Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices 
Talia Spanier, MDa, Mehmet Oz, MDa, Howard Levin, MDb, Alan Weinberg, MSc, Kathy Stamatis, MSc, David Stern, MDa,d, Eric Rose, MDa, Ann Marie Schmidt, MDa,b  The Journal of Thoracic and Cardiovascular Surgery  Volume 112, Issue 4, Pages (October 1996) DOI: /S (96) Copyright © 1996 Mosby, Inc. Terms and Conditions

2 Fig. 1 Assessment of routine coagulation parameters in patients with LVADs and patients with end-stage heart failure (ESHF). Plasma was obtained by peripheral venipuncture from the patients with LVADs or end-stage heart failure as described in the text. Parameter (normal control) values were obtained from the clinical coagulation laboratory of Columbia Presbyterian Medical Center. Mean values ± standard deviation for prothrombin time, activated partial thromboplastin time, and levels of platelets and fibrinogen are depicted within the bar graphs. No significant differences were noted except that patients with end-stage heart failure had higher levels of fibrinogen than patients with LVADs and normal control subjects (p < 0.02). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

3 Fig. 1 Assessment of routine coagulation parameters in patients with LVADs and patients with end-stage heart failure (ESHF). Plasma was obtained by peripheral venipuncture from the patients with LVADs or end-stage heart failure as described in the text. Parameter (normal control) values were obtained from the clinical coagulation laboratory of Columbia Presbyterian Medical Center. Mean values ± standard deviation for prothrombin time, activated partial thromboplastin time, and levels of platelets and fibrinogen are depicted within the bar graphs. No significant differences were noted except that patients with end-stage heart failure had higher levels of fibrinogen than patients with LVADs and normal control subjects (p < 0.02). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

4 Fig. 1 Assessment of routine coagulation parameters in patients with LVADs and patients with end-stage heart failure (ESHF). Plasma was obtained by peripheral venipuncture from the patients with LVADs or end-stage heart failure as described in the text. Parameter (normal control) values were obtained from the clinical coagulation laboratory of Columbia Presbyterian Medical Center. Mean values ± standard deviation for prothrombin time, activated partial thromboplastin time, and levels of platelets and fibrinogen are depicted within the bar graphs. No significant differences were noted except that patients with end-stage heart failure had higher levels of fibrinogen than patients with LVADs and normal control subjects (p < 0.02). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

5 Fig. 1 Assessment of routine coagulation parameters in patients with LVADs and patients with end-stage heart failure (ESHF). Plasma was obtained by peripheral venipuncture from the patients with LVADs or end-stage heart failure as described in the text. Parameter (normal control) values were obtained from the clinical coagulation laboratory of Columbia Presbyterian Medical Center. Mean values ± standard deviation for prothrombin time, activated partial thromboplastin time, and levels of platelets and fibrinogen are depicted within the bar graphs. No significant differences were noted except that patients with end-stage heart failure had higher levels of fibrinogen than patients with LVADs and normal control subjects (p < 0.02). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

6 Fig. 2 Assessment of thrombin generation in patients with LVADs and in patients with end-stage heart failure (ESHF). Peripheral blood was obtained as described in the text and plasma was assayed as described for F1+2 and TAT. Mean values ± standard deviation are shown within the bar graphs. Levels of F1+2 and TAT were significantly higher in patients with LVADs than in patients with end-stage heart failure and than the normal control values (p < and p < , respectively). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

7 Fig. 3 Assessment of activation of fibrinolysis in patients with LVADs and patients with end-stage heart failure (ESHF). Peripheral blood was obtained as described in the text and plasma was assayed as described for levels of D-dimers and FDPs. Mean values ± standard deviation are shown within the bar graphs. Levels of D-dimers were significantly higher in patients with LVADs than in patients with end-stage heart failure and than the normal control values (p < and p < 0.002, respectively). Levels of FDPs were significantly higher in patients with LVADs than in patients with end-stage heart failure and than the normal control values (p < and p < , respectively). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

8 Fig. 4 Elevation of soluble thrombomodulin in patients with LVADs: a possible marker of endothelial perturbation. Peripheral blood was obtained as described in the text and plasma was assayed as described for levels of soluble thrombomodulin. Mean values of soluble thrombomodulin ± standard deviation are shown within the bar graphs. Levels of soluble thrombomodulin were significantly higher in patients with LVADs than the normal control values (p < 0.002). There was no significant difference in levels of soluble thrombomodulin in patients with LVADs and patients with end-stage heart failure sustained without anticoagulation. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

9 Fig. 5 Soluble thrombomodulin. We postulate that soluble thrombomodulin, likely derived from the integral membrane protein constitutively expressed by the endothelium, is shed and/or proteolyzed as a result of endothelial perturbation caused by the presence of the LVAD. Such inciting causes as the presence of microemboli in a procoagulant milieu, altered flow characteristics with cellular activation, and/or other vascular factors associated with the LVAD itself are likely contributory factors. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

10 Fig. 6 Coagulation cascade/fibrinolysis. As demonstrated by our studies, evidence exists for significant thrombin generation (as reflected by increased levels of TAT and F1+2) and fibrinolysis (increased levels of D-dimers and FDPs) in patients with LVADs compared with values for the normal control population and values for patients with end-stage heart failure not supported by LVAD or anticoagulant therapy. The mechanism(s) underlying the generation of a procoagulant state are not yet clear. For example, it is not known whether activation of the intrinsic and/or extrinsic pathways of coagulation underlie these findings. Closed arrows are indicative of the procoagulant pathway resulting in the formation of a fibrin clot. Open arrows follow the fibrinolytic pathway. Dotted arrows and open font signify the markers of these pathways reported in this study. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

Download ppt "Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices  Talia Spanier, MDa, Mehmet Oz, MDa, Howard Levin,"

Similar presentations

DIC disseminated intravascular coagulation DIC is characterized by widespread coagulation and bleeding in the vascular compartment. DIC begins with massive.

DIC disseminated intravascular coagulation DIC is characterized by widespread coagulation and bleeding in the vascular compartment. DIC begins with massive.
Investigation of Haemostasis MS. c. program Lab-9.

Investigation of Haemostasis MS. c. program Lab-9.
Blood Plasma Plasma –Liquid part of blood –Clear, straw-colored fluid –90% water and 10% solutes –Solutes 6% to 8% of solutes are proteins –Albumins—helps.

Blood Plasma Plasma –Liquid part of blood –Clear, straw-colored fluid –90% water and 10% solutes –Solutes 6% to 8% of solutes are proteins –Albumins—helps.
Chapter 17 Coagulation Testing

Chapter 17 Coagulation Testing
Principles of Blood Coagulation

Principles of Blood Coagulation
Robert C. Gorman, MDa(by invitation), Nicholas P

Robert C. Gorman, MDa(by invitation), Nicholas P
Peter E. Ballmer, MDa, Walter H

Peter E. Ballmer, MDa, Walter H
Monitoring and Treatment of Coagulation Disorders in End-Stage Liver Disease Visc Med 2016;32:241-248 - DOI:10.1159/000446304 Fig. 1. On the left side,

Monitoring and Treatment of Coagulation Disorders in End-Stage Liver Disease Visc Med 2016;32: DOI: / Fig. 1. On the left side,
Hypercoagulable States

Hypercoagulable States
Effects of myocardial ischemia on the release of cardiac troponin I in isolated rat hearts  Sidney Chocron, MDa, Kifah Alwan, MDa, Gerard Toubin, MDb,

Effects of myocardial ischemia on the release of cardiac troponin I in isolated rat hearts  Sidney Chocron, MDa, Kifah Alwan, MDa, Gerard Toubin, MDb,
Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations  Jari Petäjä, MDa, Kaija Peltola, MDa, Heikki Sairanen, MDa, Mauri.

Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations  Jari Petäjä, MDa, Kaija Peltola, MDa, Heikki Sairanen, MDa, Mauri.
Stephen H. McKellar, MD, MSc, Stuart Abel, BS, Christopher L

Stephen H. McKellar, MD, MSc, Stuart Abel, BS, Christopher L
Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog  Talia B. Spanier, MDa, Mehmet C. Oz, MDa, Oktavijan.

Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog  Talia B. Spanier, MDa, Mehmet C. Oz, MDa, Oktavijan.
The Hematologic System as a Marker of Organ Dysfunction in Sepsis

The Hematologic System as a Marker of Organ Dysfunction in Sepsis
Coagulation, fibrinolysis, and platelet activation in patients undergoing open and endovascular repair of abdominal aortic aneurysm  Robert S.M. Davies,

Coagulation, fibrinolysis, and platelet activation in patients undergoing open and endovascular repair of abdominal aortic aneurysm  Robert S.M. Davies,
Peter E. Ballmer, MDa, Walter H

Peter E. Ballmer, MDa, Walter H
Selective anticoagulation with active site-blocked factor IXa suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary.

Selective anticoagulation with active site-blocked factor IXa suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary.
New anticoagulant coatings and hemostasis assessment tools to avoid complications with pediatric left ventricular assist devices  Daniel C. Leslie, PhD,

New anticoagulant coatings and hemostasis assessment tools to avoid complications with pediatric left ventricular assist devices  Daniel C. Leslie, PhD,
Richard J. Kaplon, MDa, Mehmet C. Oz, MDa, Pawel A

Richard J. Kaplon, MDa, Mehmet C. Oz, MDa, Pawel A
Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant.

Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant.

Similar presentations

Ads by Google